
    
      This study is designed to evaluate the efficacy and safety of Pyrotinib in patients with HER2
      positive advanced pre-treated Non-small cell lung cancer.

      To observe objective response rate (ORR) of pyrotinib in HER2 positive NSCLC. To observe
      Progression free survival （PFS）. To assess the overall survival (OS). To assess side effects.
      To evaluate quality of life. To explore the relationship between biomarkers and the
      toxicity/efficacy of Pyrotinib.
    
  